IDEAYA Biosciences (IDYA) Liabilities and Shareholders Equity (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 6.39% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (down 1.63% YoY), and the FY2025 full-year result was $1.1 billion, down 1.31% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.0 billion in Q1 2026, from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q3 2024 to a low of $338.0 million in Q2 2022.
• A 5-year average of $784.5 million and a median of $961.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 163.62% in 2024 and decreased 6.39% in 2026, its largest moves.
• Tracing IDYA's Liabilities and Shareholders Equity over 5 years: stood at $388.0 million in 2022, then jumped by 67.36% to $649.3 million in 2023, then surged by 73.12% to $1.1 billion in 2024, then fell by 1.31% to $1.1 billion in 2025, then dropped by 7.12% to $1.0 billion in 2026.
• Business Quant data shows IDYA's Liabilities and Shareholders Equity at $1.0 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.2 billion in Q3 2025.